Lv61
1980 积分 2023-03-30 加入
Molecularly Targeted Therapies for Triple Negative Breast Cancer: History, Advances, and Future Directions
2天前
已完结
Fuzuloparib with or without apatinib in patients with HER2-negative metastatic breast cancer with germline BRCA1/2 mutations (FABULOUS): interim analysis of a multicentre, three-arm, open-label, randomised, phase 3 trial
4天前
已完结
Switch to fulvestrant and palbociclib versus no switch in advanced breast cancer with rising ESR1 mutation during aromatase inhibitor and palbociclib therapy (PADA-1): a randomised, open-label, multicentre, phase 3 trial
5天前
已完结
The CDK4/6 inhibitors biomarker landscape: The most relevant biomarkers of response or resistance for further research and potential clinical utility
5天前
已完结
微卫星高度不稳定型胃癌治疗与耐药的研究进展
7天前
已完结
Epidemiology, pathogenesis, biology and evolving management of MSI-H/dMMR cancers
7天前
已完结
Precision therapeutics and emerging strategies for HR-positive metastatic breast cancer
9天前
已完结
Investigation of Immunogenicity Assessment of Biosimilar Monoclonal Antibodies in the United States
17天前
已完结
MYB/NFIB基因融合与头颈腺样囊性癌分级和预后相关性及检测方法一致性研究
24天前
已完结
Surrogate End Points for Overall Survival in Neoadjuvant Randomized Clinical Trials for Early Breast Cancer
1个月前
已完结
皖公网安备34019202002308
